联合化疗市场规模、份额及成长分析（按产品类型、组合类型、应用、最终用户和地区）－2025-2032 年产业预测

预计 2023 年全球联合化疗市场价值将达到 57.8 亿美元，并从 2024 年的 61.5 亿美元增长到 2032 年的 101 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.4%。

全球联合化疗市场正在经历强劲成长，主要原因是癌症发生率的上升和药物组合技术的进步。老年人口日益增多，易患癌症，凸显了个人化治疗方案的必要性。然而，市场面临的挑战包括严格的法律规范和药房业务方面的安全问题，凸显了合规性和病人安全的重要性。另一方面，创新复合技术的开发、精准医疗的普及等新的商业机会也正在涌现，预计将进一步激发市场活力。整体而言，这一前景代表着挑战和进步的交汇，将决定联合化疗的未来。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

联合化疗市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 注射剂
• 局部的

联合化疗市场规模（按组合类型和复合年增长率） (2025-2032)

• 市场概览
• 已灭菌
• 非无菌

联合化疗市场规模：按应用和复合年增长率（2025-2032）

• 市场概览
• 肿瘤学
• 血液学
• 其他的

联合化疗市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院
• 专科诊所
• 居家照护环境
• 其他的

联合化疗市场规模：按地区及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• B. Braun Melsungen AG（Germany）
• Fagron NV（Netherlands）
• Baxter International Inc.（USA）
• Fresenius Kabi AG（Germany）
• BioScrip, Inc.（USA）
• Advanced Pharma, Inc.（USA）
• PharMEDium Services, LLC（USA）
• QuVa Pharma, Inc.（USA）
• Nephron Pharmaceuticals Corporation（USA）
• Central Admixture Pharmacy Services, Inc.（USA）
• McGuff Compounding Pharmacy Services, Inc.（USA）
• Cantrell Drug Company（USA）
• Triangle Compounding Pharmacy（USA）
• Wedgewood Pharmacy（USA）
• Pencol Compounding Pharmacy（USA）
• Smiths Medical（USA）
• ICU Medical, Inc.（USA）
• Option Care Health, Inc.（USA）
• Pharmedium Services, LLC（USA）

结论和建议

Global Compounding Chemotherapy Market size was valued at USD 5.78 billion in 2023 and is poised to grow from USD 6.15 billion in 2024 to USD 10.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The global compounding chemotherapy market is experiencing robust growth, primarily driven by rising cancer incidence and advancements in pharmaceutical compounding technologies. The growing elderly demographic, which is more prone to cancer, underscores the necessity for personalized treatment solutions. However, the market contends with challenges such as stringent regulatory frameworks and safety concerns related to compounding practices, highlighting the critical importance of compliance and patient safety. On a positive note, emerging opportunities abound, including the development of innovative compounding technologies and the rising adoption of precision medicine, which are set to propel the market further. Overall, the landscape illustrates a blend of challenges and advancements that shape the future of compounding chemotherapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Compounding Chemotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Compounding Chemotherapy Market Segments Analysis

Global Compounding Chemotherapy Market is segmented by Product Type, Compounding Type, Application, End User and region. Based on Product Type, the market is segmented into Oral, Injectable and Topical. Based on Compounding Type, the market is segmented into Sterile and Non-Sterile. Based on Application, the market is segmented into Oncology, Hematology and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Compounding Chemotherapy Market

The global compounding chemotherapy market is experiencing significant growth driven by the shift towards personalized medicine. As healthcare providers increasingly recognize the importance of individualized treatment plans, there is a heightened demand for customized chemotherapy solutions. Compounding chemotherapy is well-positioned to take advantage of this trend by providing therapies tailored to meet specific patient needs. This includes taking into account unique factors such as genetic profiles, disease characteristics, and individual responses to treatments. By enabling the formulation of bespoke medications, compounding chemotherapy aligns with the evolving healthcare landscape, where personalized approaches are deemed crucial to enhancing treatment efficacy and improving patient outcomes.

Restraints in the Global Compounding Chemotherapy Market

A significant obstacle facing the global compounding chemotherapy market is the lack of standardized practices and formulations. This inconsistency in compounding methodologies raises serious concerns regarding the dependability and effectiveness of compounded chemotherapy medications. Variations in drug formulation, stability, and potency can lead to fluctuations in treatment outcomes for patients, undermining the overall therapeutic effectiveness. Furthermore, the absence of uniform protocols complicates the ability of healthcare providers to assess and compare various compounded formulations, creating additional challenges in ensuring optimal patient care. This variability not only impacts patient safety but also hinders the overall advancement of the compounding chemotherapy sector.

Market Trends of the Global Compounding Chemotherapy Market

The Global Compounding Chemotherapy market is experiencing a transformative trend driven by advances in pharmacogenomics. As healthcare providers increasingly recognize the importance of individualized treatment, the integration of genetic profiling into compounding chemotherapy is becoming paramount. This trend allows for medications to be specifically tailored to a patient's unique genetic makeup, enhancing treatment efficacy and reducing the likelihood of adverse reactions. As a result, the demand for personalized compounding services is rising, propelling market growth. Additionally, increased collaboration among oncologists, pharmacists, and geneticists further supports the expansion of this market, positioning it for significant developments in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Compounding Chemotherapy Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Compounding Chemotherapy Market Size by Compounding Type & CAGR (2025-2032)

• Market Overview
• Sterile
• Non-Sterile

Global Compounding Chemotherapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Hematology
• Others

Global Compounding Chemotherapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Compounding Chemotherapy Market Size & CAGR (2025-2032)

• North America (Product Type, Compounding Type, Application, End User)
  • US
  • Canada
• Europe (Product Type, Compounding Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Compounding Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Compounding Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Compounding Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fagron NV (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioScrip, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharMEDium Services, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuVa Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nephron Pharmaceuticals Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Central Admixture Pharmacy Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McGuff Compounding Pharmacy Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cantrell Drug Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Triangle Compounding Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wedgewood Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pencol Compounding Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICU Medical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Option Care Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmedium Services, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations